Eli Lilly threatens Zepbound copycat makers

Digest more
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
Eli Lilly is coming after makers of copycat versions of Zepbound
Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.
Eli Lilly sues more US pharmacies as weight loss squeeze increases
Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing competition and patent expiration increase urgency for Lilly | New Jersey and Delaware stores accused of selling unapproved tirzepatide-based products.

Hims, Lilly and Zepbound

Digest more
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on its platform. Shares of the company were up 8.5% in afternoon trading. The telehealth firm is following its peers Teladoc and LifeMD in offering Lilly's Zepbound ahead of restrictions on selling copies known as compounded drugs.
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform
Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.
‘Don’t Fall for the Hype,’ Says Top Analyst about HIMS’ Decision to Sell Zepbound
Shares of Hims & Hers Health (HIMS) rallied on Tuesday after the telehealth company said it would begin selling branded versions of Eli
The Pharma Letter4h
Lilly defends market with new action against GLP-1 compounders
With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...
Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
Eli Lilly (LLY) is targeting additional drug compounders and telehealth companies that make copycat versions of its weight loss drug, with ...
Hims & Hers shares rise as company adds Eli Lilly's Zepbound
CNBC's Brandon Gomez joins 'Closing Bell' to discuss Hims & Hers shares rising as company adds new weight-loss medications to ...